Corcept Therapeutics | CORT - Operating Profit

Stock Price
56.37
Daily Change
-1.93 -3.31%
Monthly
28.23%
Yearly
-24.92%
Q2 Forecast
55.24

Corcept Therapeutics reported $-49.6M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Alaunos Therapeutics USD -1.19M 148K Sep/2025
ANI Pharmaceuticals USD 38.71M 9.58M Mar/2026
Ardelyx USD 5.1M 431K Dec/2025
Assertio Holdings USD -3.05M 569K Sep/2024
Aurora Cannabis CAD -35.79M 19.88M Dec/2025
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Canopy Growth CAD -12.66M 1.64M Dec/2025
Corcept Therapeutics USD -49.6M 54.09M Mar/2026
Eli Lilly USD 9.78B 792M Mar/2026
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
J&J USD 6.62B 1.03B Mar/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
Merck USD -1.88B 8.12B Mar/2026
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Novartis USD 4.24B 171M Mar/2026
Novartis USD 4.06B 521M Dec/2025
Omeros USD -35.41M 23.75M Sep/2024
Pacira USD 4.62M 1.43M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Supernus Pharmaceuticals USD -35.25M 49.07M Mar/2026
TG Therapeutics USD 34.8M 15.7M Mar/2026